Pseudomonas aeruginosa is an opportunistic bacterial pathogen associated with severe nosocomial infections in immunocompromised hosts and patients with cystic fibrosis (CF). During infection the bacteria secrete proteins that are essential to the infection process. Several of these virulence-associated proteins have been identified using genetic methods. The aim of this research, using a proteomic approach, was to identify novel extracellular proteins that are secreted by P. aeruginosa during infection of a CF patient. Extracellular proteins from P. aeruginosa strain PAO1 grown in vitro were separated by two-dimensional gel electrophoresis (2-DE). The humoral response of chronically infected CF patients to the separated proteins was elucidated using western blotting. Growth phase, cell population and iron limitation were identified as important regulators of the extracellular proteome. The number of extracellular proteins significantly increased upon entry into stationary phase, as did the number of proteins detected by CF patient sera. The detection of several known quorum-controlled proteins by patient sera indicated the importance of this regulatory mechanism during infection. In iron-limiting medium, the proportion of proteins detected by CF patient sera significantly increased compared to extracellular proteins from cells grown in iron-replete conditions. Proteomic analysis of a PAO1 pvdS mutant strain showed that PvdS (an iron-regulated alternative sigma factor) directs production of many extracellular proteins made during infection of a CF patient. Examination of extracellular proteins from a second strain, PA4, indicated it had a shared set of extracellular proteins. The identities of selected proteins were determined and these included well-characterised extracellular virulence factors such as elastase (LasB). Also identified were proteins with a potential virulence role such as azurin (a copper containing redox protein), PA2939 (a likely aminopeptidase) and proteins with unknown functions. This study provides the first evidence for the production of these proteins during infection. In summary, the proteomics methodology developed here facilitated the rapid identification and enumeration of proteins secreted by P. aeruginosa during infection.

<i>Aeromonas hydrophila</i> uses the type II secretion system to transport protein toxins across the outer membrane. The trans-envelope system is comprised of more than ten proteins, including ExeA and ExeB, which form a complex in the inner membrane and are required for assembly of the ExeD secretion channel multimer, called the secretin, into the outer membrane. A putative peptidoglycan binding domain (Pfam protein families database number PF01471) is present in the periplasmic region of ExeA (pExeA), leading to the hypothesis that ExeA generates gaps in peptidoglycan, a barrier for trans-envelope transport and apparatus assembly, to allow ExeD to assemble into the outer membrane.<p> In this study, interactions between ExeA and peptidoglycan were examined both <i>in vivo</i> and <i>in vitro</i>. Wild type ExeA, but not the mutants containing substitution mutations of three highly conserved amino acid residues in the putative peptidoglycan binding domain, was cross-linked to peptidoglycan in vivo with DTSSP. Furthermore, the presence of wild type ExeA was also required for co-crosslinking of ExeB and ExeC to peptidoglycan. <i>In vitro</i> cosedimentation revealed that purified pExeA was able to bind to highly purified peptidoglycan. The protein assembled into large multimers in the presence of peptidoglycan fragments, as shown in cross-linking and co-gel filtration experiments. The requirement of peptidoglycan for multimerization was abrogated when the protein was incubated at temperatures above 25 °C. Two pExeA constructs, which disrupted the putative peptidoglycan binding domain, greatly reduced the cosedimentation, accompanied by decreased multimerization in the presence of peptidoglycan fragments. These results provide evidence that the putative peptidoglycan binding domain of ExeA is involved in physical contact with peptidoglycan. The interactions cause ExeA to multimerize, possibly forming a ring-like structure on the peptidoglycan, to generate a gap large enough to accommodate the secretion apparatus and/or to form an assembly scaffold.<p> The putative peptidoglycan binding domain of ExeA was also analyzed by comparing its amino acid sequence with that of other homologues. The highly conserved amino acid residues were found to cluster at one pocket on the surface in the crystal structure of hydrolase metallo (Zn) DD-peptidase that also contains this domain. We propose that this pocket is the binding site for the peptidoglycan ligand.

<i>Aeromonas hydrophila</i> uses the type II secretion system to transport protein toxins across the outer membrane. The trans-envelope system is comprised of more than ten proteins, including ExeA and ExeB, which form a complex in the inner membrane and are required for assembly of the ExeD secretion channel multimer, called the secretin, into the outer membrane. A putative peptidoglycan binding domain (Pfam protein families database number PF01471) is present in the periplasmic region of ExeA (pExeA), leading to the hypothesis that ExeA generates gaps in peptidoglycan, a barrier for trans-envelope transport and apparatus assembly, to allow ExeD to assemble into the outer membrane.<p> In this study, interactions between ExeA and peptidoglycan were examined both <i>in vivo</i> and <i>in vitro</i>. Wild type ExeA, but not the mutants containing substitution mutations of three highly conserved amino acid residues in the putative peptidoglycan binding domain, was cross-linked to peptidoglycan in vivo with DTSSP. Furthermore, the presence of wild type ExeA was also required for co-crosslinking of ExeB and ExeC to peptidoglycan. <i>In vitro</i> cosedimentation revealed that purified pExeA was able to bind to highly purified peptidoglycan. The protein assembled into large multimers in the presence of peptidoglycan fragments, as shown in cross-linking and co-gel filtration experiments. The requirement of peptidoglycan for multimerization was abrogated when the protein was incubated at temperatures above 25 °C. Two pExeA constructs, which disrupted the putative peptidoglycan binding domain, greatly reduced the cosedimentation, accompanied by decreased multimerization in the presence of peptidoglycan fragments. These results provide evidence that the putative peptidoglycan binding domain of ExeA is involved in physical contact with peptidoglycan. The interactions cause ExeA to multimerize, possibly forming a ring-like structure on the peptidoglycan, to generate a gap large enough to accommodate the secretion apparatus and/or to form an assembly scaffold.<p> The putative peptidoglycan binding domain of ExeA was also analyzed by comparing its amino acid sequence with that of other homologues. The highly conserved amino acid residues were found to cluster at one pocket on the surface in the crystal structure of hydrolase metallo (Zn) DD-peptidase that also contains this domain. We propose that this pocket is the binding site for the peptidoglycan ligand.

No description available.

Abstract Type XII minicollagen chain association was studied using baculovirus-directed insect cell expression. Since insect cells contain low endogenous prolyl 4-hydroxylase activity, the mechanism of the effect of prolyl hydroxylation on trimer formation in this collagen could be studied directly by adding recombinant baculoviruses directing the synthesis of prolyl 4-hydroxylase. Prolyl 4-hydroxylase was shown to be involved in the trimeric assembly process of type XII collagen through its α subunit, and thus through its hydroxylase activity. The transmembrane protein type XIII collagen was also characterized by means of insect cell expression, for which purpose new antibodies against its non-collagenous domains NC2 and NC4 were generated, together with a pan-collagen antibody against collagenous sequences. Type XIII collagen α chains were found to form disulphide-bonded homotrimers, and this was enhanced by prolyl 4-hydroxylation. Analysis of the disulphide-bonding pattern of the eight cysteine residues of the α1(XIII) chains revealed that some of the cysteines in the NC1 domain, and possibly the cysteines at the junction of the COL1 and NC2 domains, are interchain-linked, while the cysteines in the NC4 domain are intrachain-linked. The three collagenous domains of type XIII collagen were shown to be in triple-helical conformation and have different thermal stabilities, i.e. 38±C for the COL1 domain, 49±C for COL2 and 40±C for COL3. Furthermore, it was shown that type XIII collagen is oriented in the plasma membrane of insect cells so that its non-collagenous N-terminus is intracellular and its mostly collagenous C-terminus is extracellular. Type XIII collagen was also found to be cleaved into the insect cell culture medium by a furin-like protease. The expression of various type XIII collagen deletion variants suggested that chain recognition and the association of type XIII collagen α chains into trimers occur in the N-terminal portion of this molecule. An internal in-frame deletion of residues 63-83 immediately adjacent to the transmembrane domain indicated that this short ectodomain sequence is necessary for the formation of disulphide-bonded trimers. Since a sequence homologous with these deleted residues was also found at the same plasmamembrane-adjacent location in other collagenous transmembrane proteins, this points to common features in their chain association.

Abstract The carbonic anhydrases (CAs) participate in the maintenance of pH homeostasis in various tissues of the human body by catalyzing the reversible reaction CO2 + H2O ⇔ HCO3- + H+. Carbonic anhydrase isoenzyme VI (CA VI) is secreted into the human saliva by the serous acinar cells of the parotid and submandibular glands. The present work was undertaken in order to gain an understanding of the physiological role of CA VI in the oral cavity. CA VI concentrations were compared with other salivary characteristics and with the clinical dental status of the subjects. Saliva samples were collected under strictly controlled conditions from 209 young, healthy men and their CA VI concentrations determined by means of a specific time-resolved immunofluorometric assay. Salivary secretion rate, pH, buffering capacity, α-amylase activity level and counts of lactobacilli and mutans streptococci were also determined. Salivary CA VI concentrations showed positive correlations with salivary secretion rate (r = 0.20, p = 0.003) and amylase activity level (r = 0.46, p &lt; 0.001), but not with pH, buffering capacity, or counts of mutans streptococci or lactobacilli. Salivary CA VI concentration, pH and buffering capacity correlated negatively with the number of decayed, missing or filled teeth (DMFT index). The correlation between salivary CA VI concentration and DMFT index was closest in the subjects with poor oral hygiene. No correlation was found between salivary secretion rate or amylase activity and the DMFT index. The location of CA VI in the enamel pellicle, a thin layer of proteins on dental surfaces providing a protective interface between the tooth surface and the external environment, was demonstrated in samples of extracted teeth using immunostaining with anti-CA VI antibody. Immunostaining for salivary α-amylase, which was used as a positive control, produced virtually the same staining patterns. The presence of CA VI in the natural enamel pellicle was confirmed by Western blotting of pellicle proteins. Histochemical staining of enamel pellicle formed in vitro showed that the bound enzyme retains its CA activity. To determine whether CA VI is transferred into the circulation, blood and saliva samples were collected from four healthy male volunteers at 3-h intervals throughout a 24-h period and assayed for CA VI concentration. CA VI was present in all the serum samples, although its concentration was about 22 times lower than in the saliva. The presence of CA VI in serum was confirmed using a sensitive Western blotting method. Western blotting also showed that serum CA VI is associated with IgG, which may protect the enzyme from proteolytic degradation or target it to sites that do not contain CA VI. The present results suggest that salivary CA VI is not involved in regulation of the actual pH or buffering capacity of the saliva, but it does seem to have a specific role in the oral cavity. High salivary concentrations of CA VI appear to be associated with low caries experience. Since active CA VI is located in the enamel pellicle, it may function locally in the microenvironment of the dental surfaces and accelerate the neutralization of the acid metabolic products of bacterial plaque.

Many studies in different eukaryotes have shown the importance of the vesicle-tethering exocyst complex for cellular processes dependent on intensive polarized secretion. The plant exocyst complex is crucial for regulation of cell polarity, morphogenesis, and defence. In land plants, gene encoding the EXO70 exocyst subunit multiplied into many paralogs, but only a few of them have been functionally described. In this thesis, the EXO70A2 isoform, a member of the EXO70.1 subfamily, was found to be the main EXO70 exocyst subunit involved in the canonical function of the exocyst complex in Arabidopsis pollen. EXO70A2 is important for several stages of pollen development-pollen grain maturation, germination, and pollen tube growth. Pollen-expressed EXO70A2 was the only EXO70 isoform able to substitute for the function of EXO70A1 in the sporophyte, but not vice-versa. This indicates partial functional redundancy of these two closely related isoforms and a high specificity for pollen-related processes. The finding that the exocyst is targeted to the plasma membrane via EXO70A1 subunit is further elaborated in the thesis. EXO70A1 binds plasma membrane via interactions with specific phospholipids that form a unique plasma membrane-lipid signature in plants. Other isoform, EXO70B1 from the EXO70.2 subfamily,...

No description available.

No description available.

Chlamydia is the most prevalent sexually transmitted bacterial infection in many developed countries, including Canada. Untreated infections in women can lead to a number of complications including pelvic inflammatory disease, tubal factor infertility, and ectopic pregnancy. Public health programs, including screening for at-risk individuals, partner identification, and antibiotic treatment, have had limited success in controlling the rising incidence of chlamydial infections over the past two decades. A chlamydia vaccine that prevents infection and its pathological sequelae is the next essential step to control this persistent public health problem. Chlamydia spp. utilize the highly conserved type III secretion (T3S) system as an essential virulence factor for infection and intracellular replication. Here, we evaluated a novel chimeric antigen (BD584) consisting of three T3S proteins from C. trachomatis (CopB, CopD, and CT584) as a potential chlamydia vaccine candidate. Intranasal immunization with BD584 elicited strong humoral responses that neutralized infection in vitro. Following intravaginal challenge with C. muridarum, immunized mice had a 95% reduction in chlamydial shedding and a 87.5% reduction in incidence of upper genital tract pathology compared to control mice. BD584 immunization generated strong cell-mediated and mucosal antibody responses in mice with different genetic backgrounds, and conferred protection against an intravaginal C. trachomatis infection in two out of three strains of mice. BD584 formulated with NE01, a mucosal adjuvant known to be safe and effective in humans, was shown to be highly immunogenic and efficacious against C. trachomatis infection in mice. These results suggest that BD584 may represent a promising antigen for use in a chlamydia vaccine. / Thesis / Doctor of Philosophy (PhD) / Chlamydia is the most common sexually transmitted bacterial infection in the world. The goal of this thesis is to evaluate a novel chlamydia vaccine in a mouse model of genital chlamydia infection. We engineered a fusion protein, BD584, made up of three highly conserved type III secretion (T3S) proteins CopB, CopD, and CT584. We show that vaccination with BD584 generated strong immune responses and protected mice from chlamydia infection and the associated reproductive tract disease. Interestingly, the level of protection afforded by BD584 vaccination is dependent upon the genetic background of the animal. Furthermore, we have identified particular antibody subtypes directed against BD584 as markers of BD584-mediated protective immunity. Lastly, we show that vaccination with BD584 formulated with a clinically safe and effective mucosal adjuvant generates robust immune responses and confers protection against chlamydia in mice. Together, these results provide support for the use of T3S proteins in a chlamydia vaccine.